Physician profile
Alexander S Engelman
NPI 1679863658
$80,002.96
in general payments reported to CMS, 2019-2025
45 companies · $34K in 2025
The $34K reported for 2025 was more than what 99% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $780 · 2021: $3,213 · 2022: $2,864 · 2023: $21K · 2024: $17K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Consulting Fee: $12K · Food and Beverage: $9,249 · Travel and Lodging: $5,106 · Education: $33.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,027.00 |
| Consulting Fee | $12,232.63 |
| Food and Beverage | $9,249.02 |
| Travel and Lodging | $5,105.65 |
| Education | $33.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $36,683.42 | 2019-2025 | |
| Janssen Biotech, INC. | $20,704.79 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Pfizer INC. | $5,958.09 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $3,521.38 | 2022-2025 | |
| Astellas Pharma Global Development | $1,650.00 | 2025 | Xtandi |
| Janssen Global Services, LLC | $1,470.00 | 2025 | Erleada |
| Dendreon Pharmaceuticals LLC | $1,378.22 | 2019-2025 | Provenge |
| Myriad Genetic Laboratories, INC. | $1,273.17 | 2021-2025 | Myrisk, Prolaris |
| Blue Earth Diagnostics | $1,032.73 | 2020-2025 | Posluma |
| Palette Life Sciences, INC. | $962.23 | 2021-2022 | |
| Astellas Pharma US INC | $493.52 | 2019-2025 | Xtandi |
| Boston Scientific Corporation | $474.91 | 2019-2024 | Spaceoar Vue System - 10ml |
| Sumitomo Pharma America, INC. | $385.51 | 2023-2025 | Orgovyx |
| Progenics Pharmaceuticals, INC. | $382.13 | 2022-2025 | Pylarify |
| Isoray, INC | $292.40 | 2022-2024 | Brachytherapy Source |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $289.80 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $289.16 | 2019-2025 | Lynparza, Tagrisso |
| Merck Sharp & Dohme LLC | $281.73 | 2021-2025 | Lynparza, Keytruda, Welireg |
| Medtec LLC | $272.00 | 2020 | |
| Siemens Medical Solutions USA, INC. | $213.80 | 2021 | |
| Abbvie INC. | $204.28 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $196.00 | 2021-2025 | Yonsa |
| Axonics, INC. | $170.02 | 2022-2023 | Axonics |
| Tolmar, INC. | $140.81 | 2024-2025 | Eligard |
| Amgen INC. | $140.32 | 2020-2022 | |
| Teleflex LLC | $129.90 | 2023-2025 | Urolift, Barrigel |
| Accord Healthcare, INC. | $128.57 | 2023-2025 | |
| Foundation Medicine, INC. | $119.55 | 2021-2023 | |
| Telix Pharmaceuticals | $107.75 | 2023-2025 | Illuccix |
| Novocure INC. | $90.94 | 2020-2025 | Optune Gio |
| Caris Mpi, INC. | $85.45 | 2025 | Mi Cancer Seek |
| Bioprotect Medical, INC. | $79.18 | 2024-2025 | Bioprotect Balloon Implant System |
| Angiodynamics, INC. | $58.89 | 2021-2023 | Nanoknife |
| Tolmar Pharmaceuticals, INC. | $57.37 | 2021-2022 | |
| Tempus Ai, INC | $56.03 | 2024 | Xt Cdx |
| Elekta, INC. | $52.29 | 2021 | |
| Olympus America INC. | $37.11 | 2024 | Itind System |
| Verity Pharmaceuticals INC. | $33.62 | 2023 | Trelstar |
| Napo Pharmaceuticals INC | $27.66 | 2024 | Gelclair Concentrated Oral Gel |
| Regeneron Healthcare Solutions, INC. | $26.52 | 2024 | Libtayo |
| Laborie Medical Technologies Corp. | $23.63 | 2022 | |
| Kyowa Kirin, INC. | $14.87 | 2022 | |
| Menarini Silicon Biosystems, INC. | $13.21 | 2023 | Cellsearch |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Engelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.